signaling from a self-reactive pre-BCR, owing to ubiquitous presence of self-antigen, induces negative selection and cell death 3 . Here, we observed that Ph + ALL cells consistently lack surface expression of ITAM-bearing signaling chains Igα and Igβ (Extended Data Fig. 1a ). Seemingly in contrast to compromised Igα and Igβ expression, multiple components of proximal pre-BCR signaling were activated downstream of the BCR-ABL1 tyrosine kinase (Fig. 1a ). These findings demonstrate that oncogenic BCR-ABL1 supplants ITAM-dependent signaling and mimics a constitutively active pre-BCR through engagement with its proximal signaling cascade. Besides BCR-ABL1, mimicry of BCR signaling was previously demonstrated for a number of viral oncoproteins including Epstein-Barr virus latent membrane protein 2A (LMP2A) 13 .
Reconstitution of Igα expression induced strong tyrosine phosphorylation of proximal pre-BCR signaling molecules followed by cell death (Extended Data Fig. 1b-d) . Likewise, Ph + ALL cells from three patients were highly sensitive to reactivation of ITAM-dependent signaling (LMP2A 13 ; Extended Data Fig. 1e-f) . Interestingly, activation of ITAM signaling was toxic in leukemic but not normal pre-B cells (Extended Data Fig. 1b) . We therefore tested whether BCR-ABL1-and ITAM-dependent activation of proximal pre-BCR signaling are mutually exclusive because both engage the same pre-BCR-associated tyrosine kinases. We therefore repeated activation of ITAM signaling in the presence and absence of TKItreatment (imatinib; Fig. 1b ). Seemingly paradoxically, treatment with imatinib, while designed to kill leukemia cells, rescued BCR-ABL1 ALL cells in this experimental setting and subsequent washout of imatinib reversed the protective effect (Fig. 1b) .
To pinpoint which aspect of proximal pre-BCR signaling is toxic to Ph + ALL cells, we used genetic systems for hyperactivation of Syk, Src and Btk. In contrast to Src and Btk, constitutively active Syk (Syk Myr ) induced rapid cell death ( Fig. 1b ; Extended Data Fig. 2a-d ). Hyperactive Syk was synthetically lethal in combination with oncogenic BCR-ABL1 and cytotoxic effects were mitigated by TKI-treatment (imatinib; Fig. 1b ). Like BCR-ABL1, also Syk kinase activity alone mimicked constitutively active pre-BCR signaling and was sufficient to transform mouse pre-B cells (Extended Data Fig. 2e ). Interestingly, BCR-ABL1 kinase activity induced phosphorylation of SYK at the interdomain B, which relieves the autoinhibitory conformation of Syk 14 . To study the specific function of SYK interdomain B (Y348 and Y352) tyrosines in BCR-ABL1 ALL cells, we tested loss (Y→F) and phosphomimetic gain (Y→E) of function mutants of Syk. Empty vectors, kinase-dead Syk K402R and wildtype Syk were used as controls (Fig. 1c) . In the absence of constitutive membrane-localization, wildtype Syk had only minor toxic effects on ALL cells. Interestingly, however, expression of Syk carrying phosphomimetic mutations of interdomain B tyrosines (Y348/Y352→E348/E352) induced rapid cell death (Fig. 1c) . These findings highlight the relevance of Syk interdomain B tyrosines and suggest that pharmacological approaches to increase tyrosine phosphorylation of the Syk interdomain B may be useful to kill Ph + ALL cells. To study whether Syk tyrosine kinase activity is required for induction of cell death in pre-B ALL cells, we used a Syk tyrosine kinase inhibitor, PRT06207 (PRT). Transduction with constitutively active Syk Myr induced rapid cell death, which was rescued by pre-treatment with PRT one day prior to transduction with Syk Myr ('PRT-pre'). Interestingly, one day lapse of PRT-treatment and transient hyperactivation of Syk was sufficient to commit pre-B ALL cells to cell death (Extended Data Fig. 1g ).
In the absence of direct strategies for Syk-hyperactivation, we studied pharmacological inhibition of negative regulators of Syk. In normal pre-B cells, activation of Syk downstream of the pre-BCR, is negatively regulated by inhibitory surface receptors that bear immunoreceptor tyrosine-based inhibitory (ITIM) 15 motifs in their cytoplasmic tail. A systematic screen identified 109 ITIM-bearing receptors in the human genome 16 , 63 of which are expressed in B cells. Compared to normal pre-B cells and mature B cell lymphoma, the majority of ITIM receptors were upregulated in Ph + ALL cells. Based on the ratio of expression values in Ph + ALL compared to pre-B cells and mature B cell lymphoma, PECAM1, CD300A and LAIR1 were identified among the top-ranking ITIMreceptors, which was confirmed by flow cytometry (Extended Data Fig. 3 ).
To determine whether high expression levels of ITIM-bearing receptors influence the course of human ALL, we segregated patients from two clinical trials (P9906, ECOG 2993) into two groups based on higher or lower than median expression levels of PECAM1, CD300A and LAIR1 at the time of diagnosis. Higher than median expression levels of ITIM receptors on ALL cells at the time of diagnosis predicted shorter overall and relapse-free survival (Extended Data Fig. 4a-e) . These findings identify ITIM-bearing inhibitory receptors as a novel biomarker with potential use in risk stratification of children and adults with ALL.
To measure functional consequences of ITIM-receptor deletion, pre-B cells from the bone marrow of Pecam1 −/− , Cd300a −/− as well as Lair1 fl/fl mice and wildtype controls were propagated in the presence of IL7 or transformed with BCR-ABL1 to model human Ph + ALL. Lair1 fl/fl ALL cells were retrovirally transduced with 4-OHT-inducible Cre. Loss of ITIM-receptors had no significant effects on proliferation and survival of normal pre-B cells (Extended Data Fig. 5a ). In contrast, in the absence of ITIM-bearing receptors, pre-B ALL cells underwent cellular senescence and cell cycle arrest and failed to form colonies ( Fig. 2a ; Extended Data Fig. 5a -b) in parallel with activation of cell cycle checkpoint molecules and increased levels of cytoplasmic reactive oxygen species (ROS; Extended Data Fig. 4g-h ). Importantly, inducible Cre-mediated ablation of Lair1 surface expression (Extended Data Fig. 4f ) resulted in massive hyperactivation of Syk (Y352), SRC kinases (Y416) and Erk (T202/Y204; Fig. 2b ), which promotes negative selection of autoreactive B cell clones during early B cell development 17 . In agreement with these findings, Cre-mediated deletion of Lair1 caused rapid cell death in vitro, remission of leukemia in vivo and significantly prolonged survival of transplant recipient mice (P=0.0003, log rank test; Fig. 2c-d ; Extended Data Fig. 5c ).
The surface receptors PECAM1, CD300A and LAIR1 attenuate pre-BCR signaling through ITIM-dependent recruitment and activation of inhibitory phosphatases (e.g. PTPN6, INPP5D) [7] [8] . For this reason, we performed experiments to determine whether Lair1 contributes to activation of Ptpn6 and Inpp5d. Consistent with a role of Lair1 in recruitment and activation of Ptpn6 and Inpp5d, activating tyrosine phosphorylation of Ptpn6 (Y 564 ) and Inpp5d (Y 1020 ) was reduced by 3-to 4-fold upon inducible deletion of Lair1 (Extended Data  Fig. 5d ). In genetic rescue experiments, we demonstrated that intact ITIM-motifs in the cytoplasmic tails of Pecam1, Lair1 and Cd300a are critical for the survival of pre-B ALL cells: Pecam1 −/− , Lair1 −/− and Cd300a −/− pre-B cells were transduced with GFP-tagged vectors for reconstitution of Pecam1, Lair1 and Cd300a bearing either wildtype or mutant (Y→F/A) ITIM-motifs or GFP empty vector controls, and then transformed by BCR-ABL1 (Fig. 2e-g ). Reconstitution with wildtype-ITIM Pecam1, Lair1 and Cd300a rescued survival and proliferation, whereas reconstitution with receptors carrying tyrosine-mutant ITIMs had no effect (Fig. 2e-g ).
The phosphatases PTPN6 (SHP1) 7 , INPP5D (SHIP1) 8 and PTPN11 (SHP2) 18 can all bind to ITIM-motifs. We determined their mechanistic contribution to calibration of oncogenic signaling in a genetic rescue experiment: Lair1 fl/fl ALL cells were transduced with GFPtagged expression vectors of constitutively active (CA) and phosphatase-inactive forms of Ptpn6, Inpp5d, Ptpn11 ( Fig. 3a; Extended Data Fig. 5e ). Expression of constitutively active Inpp5d and Ptpn6, but not Ptpn11, rescued Cre-mediated deletion of Lair1. Interestingly, inducible deletion of Ptpn6 or Inpp5d was sufficient to cause cell death and a sharp increase of cellular ROS levels in ALL cells ( Fig. 3b-c ; Extended Data Fig. 6b -e and 7a). Given that phosphatases are sensitive to reversible inactivation by cysteine oxidation of their active sites 19 , we tested whether deletion of one single phosphatase triggers a ROS-mediated chain-reaction of phosphatase-inactivation. Using antibodies against phosphatases in inactivated oxidized conformation, we found that deletion of either Ptpn6 or Inpp5d caused wide-spread cysteine-oxidation and inactivation of multiple other phosphatases (Extended Data Fig. 7b ). Inducible ablation of Ptpn6 and Inpp5d caused increased expression of Arf and p53 cell cycle checkpoint molecules, G 0/1 cell cycle arrest and 15-to 40-fold reduced colony formation ( Fig. 3d-e ; Extended Data Fig. 7c-e) . In an in vivo transplant experiment, inducible in vivo deletion of Ptpn6 or Inpp5d significantly reduced penetrance and extended latency of leukemia ( Fig. 3f; P<0 .0005, log-rank test). These findings reveal a novel and unexpected vulnerability and suggest that ITIM-bearing receptors and inhibitory phosphatases represent a novel class of therapeutic targets in pre-B ALL. Both PTPN6 and INPP5D attenuate ITAM-dependent pre-BCR signaling in normal pre-B cells 7, 8 . Cremediated depletion of Ptpn6 and Inpp5d protein resulted in strong hyperactivation of Syk (Y 352 ; Fig. 3g-h ). While PTPN6 directly dephosphorylates ITAMs and SYK 7 , INPP5D hydrolyzes the membrane anchor PIP3 and thereby inhibits formation and maintenance of ITAM-dependent signaling complexes at the cell membrane 20 . Pre-treatment with the Sykinhibitor PRT06207 largely rescued cell death, demonstrating that hyperactivation of Syk is a mechanistic requirement for induction of cell death (Fig. 3i-j) .
B-lineage Ph + ALL and myeloid lineage chronic myeloid leukemia (CML) are both driven by BCR-ABL1. As opposed to Ph + ALL, however, defective expression of ITIM-receptors, Ptpn6 or-Inpp5d had no functional consequences in a mouse model for CML (Extended Data Fig. 8 and 9 ). Consistent with these findings, PTPN6 and INPP5D are highly expressed in patient-derived Ph + ALL (n=5) but barely detectable in CML cells (n=5; Extended Data Fig. 10c -e). These findings support a scenario in which Ph + ALL cells are subject to B cell-specific negative selection against hyperactive Syk tyrosine kinase signaling emanating from a self-reactive BCR, or its oncogenic mimic BCR-ABL1. Inducible expression of Cebpa subverts B cell lineage commitment and raises the threshold for tyrosine kinase hyperactivation to trigger cell death. In this context, it is interesting to note that multiple genetic lesions in human pre-B ALL target transcription factors that mediate B cell lineage commitment, including IKZF1, PAX5 and EBF1 22 . While their mechanistic role is not known, we here propose that deletions of IKZF1, PAX5 and EBF1, like downregulation of PAX5 in the context of Cebpa expression, reduce stringency of negative selection against hyperactive tyrosine kinase signaling.
A small molecule inhibitor against INPP5D, 3-α-aminocholestane, 3AC 9 (Extended Data Fig. 10f ) selectively inhibited enzymatic activity of INPP5D (SHIP1; IC 50 ~2.5 μmol/l) but not related phosphatases INPP5L1 (SHIP2) and PTEN (IC 50 >20 μmol/l) 9 . Treatment of patient-derived Ph + ALL cells with 3AC induced strong hyperactivation of SYK (Fig. 4a) . In patient-derived myeloid CML samples, baseline levels of Syk activity were very low and not responsive to 3AC treatment (Extended Data Fig. 10g ). Biochemical characterization of 3AC-mediated inhibition of INPP5D in patient-derived Ph + ALL cells revealed potent and transient hyperactivation of proximal pre-BCR signaling molecules (Fig. 4a) . Treatment of patient-derived TKI-resistant Ph + ALL cells with 3AC induced cell death within four days. Importantly, pre-treatment of Ph + ALL cells with the SYK-inhibitor (PRT06207) largely protected Ph + ALL cells against 3AC-induced cell death (Fig. 4b) , demonstrating that hyperactivation of Syk is required for induction of cell death. Dose-response analyses revealed that 3AC is selectively toxic for patient-derived Ph + ALL cells (IC 50 =2.8 μmol/l; n=5) compared to mature B cell lymphoma (n=5; Extended Data Fig. 10h ). We next studied drug-responses in a panel of six cases of Ph + ALL from patients who relapsed under TKItherapy, including three cases with global TKI-resistance owing to the BCR-ABL1 T315I mutation. As expected, treatment with the TKI Imatinib had no effect in BCR-ABL1 T315I cases (Extended Data Fig. 10i ). In contrast, 3AC induced massive cell death (>95%) in all six cases of Ph + ALL regardless of BCR-ABL1 mutation status (Extended Data Fig. 10i) . Likewise, treatment of NOD/SCID transplant recipient mice carrying TKI-resistant patientderived (BCR-ABL1 T315I ) Ph + ALL cells with 3AC significantly prolonged overall survival (P=0.0002, log rank test; Fig. 4c ) and reduced leukemia burden (Fig. 4d) . While further studies are needed to optimize pharmacological targeting of this pathway, these experiments identify transient hyperactivation of SYK and engagement of negative B cell selection as a powerful new strategy to overcome drug-resistance in Ph + ALL. Table 3 ) were cultured in RPMI-1640 (Life Technologies) with GlutaMAX containing 20% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin at 37°C in a humidified incubator with 5% CO 2 . ALL of the human xenograft cells and cell lines are mycoplasma free.
Murine cell culture and BCR-ABL1 transformation
Bone marrow cells from constitutive or inducible knockout mice (for a list of genetic mouse models used in this study see Supplementary Table 4) were harvested and cultured in Iscove's modified Dulbecco's medium (IMDM, Invitrogen, Carlsbad, CA) with GlutaMAX containing 20% fetal bovine serum, 50 μM 2-mercaptoethanol, 100 IU/ml penicillin, 100 μg/ml streptomycin in the presence of cytokines. For pre-B cell culture, bone marrow cells were cultured in IMDM with 10 ng/ml recombinant mouse IL-7 (Peprotech, Rocky Hill, NJ) on OP9 stroma cells. For ALL leukemia model, pre-B cells were retrovirally transduced by BCR-ABL1. ALL cells generated from inducible knockout mice were retrovirally transduced with ERT2 or Cre ERT2 virus, and puromycin selection was performed. 4-OHT was used to induce Cre mediated gene deletion. For CML-like leukemia model, the myeloidrestricted protocol described previously was used 23 , which generates CML-like cells. Briefly, bone marrow cells were cultured in IMDM with recombinant mouse IL-3 (10 ng/ ml), IL-6 (25 ng/ml), SCF (50 ng/ml, PeproTech, Rocky Hill, NJ) and then transformed by BCR-ABL1 retroviurs. Cytokines were removed after BCR-ABL1 transduction.
In vivo transplantation of leukemia cells
Murine pre-B ALL cells transformed by BCR-ABL1 were transduced with firefly luciferase retrovirus, selected with blasticidin, and then transduced with ER T2 or Cre ER T2 virus, selected with puromycin. 4-OHT was used to induce Cre mediated gene deletion for 24 hours and 1 × 10 6 viable cells were injected into sublethally irradiated (250 cGy) NOD/ SCID mice via tail vein. For human leukemia cells, a lentiviral vector encoding firefly luciferase was used. Bioimaging of leukaemia progression in mice was performed after transplantation with an in vivo IVIS 100 bioluminescence/optical imaging system (Xenogen). 15 minutes before measuring the luminescence signal, D-luciferin (Promega) prepared in PBS was injected intraperitoneally at an amount of 2.5 mg for each mouse. General anaesthesia was induced by using 5% isoflurane and continued during the process with 2% isoflurane given through a nose cone. When a mouse was terminally sick, it was euthanized and bone marrow and spleen cells were collected for flow-cytometry analysis.
All mouse experiments were subject to institutional approval by the University of California San Francisco Institutional Animal Care and Use Committee. 6-8 week old female NOD-SCID mice were randomly allocated into each treatment group. The minimal number of mice in each group was calculated by using the 'cpower' function in R/Hmisc package. No blinding was used.
Retroviral and lentiviral transduction
Retrovirus production was performed as described previously 11 . Briefly, transfections of the retroviral constructs together with pHIT60 (gag-pol) and pHIT123 (env) were performed using Lipofectamine 2000 (Invitrogen). 10 mM sodium butyrate was used for induction. The virus supernatant was collected, filtered through a 0.45 μm filter. For lentivirus, PCD/NL-BH (gag-pol) and pMN-VSV-G (env) were used for virus packaging. The lentivirus was concentrated by centricon centrifugal filters from EMD Millipore (Billerica, MA). For transduction, non-tissue culture treated 6-well plates were coated with 50 μg/ml retronectin (Takara, Madison, WI), and virus was loaded by centrifugation (2000 × g, 90 min at 32 °C). Then virus was discarded and 2 × 10 6 pre-B cells were transduced per well by centrifugation at 600 × g for 30 minutes. Details of retroviral and lentiviral vectors used were provided in Supplementary Table 5 .
Inhibitors
BCR-ABL1 tyrosine kinase inhibitor Imatinib was obtained from LC Laboratories (Woburn, MA). INPP5D inhibitor 3-α-Aminocholestane (3AC) and Csk AS inhibitor 3-IB-PP1 were obtained from EMD Millipore (Billerica, MA). The SYK tyrosine kinase inhibitor PRT062607 was purchased from Selleck Chemicals LLC (Houston, TX).
Cell viability assay
100,000 human ALL cells were seeded in a volume of 50 μl medium in one well of a 96-well plate (BD Biosciences). Imatinib or any other inhibitor was diluted and incubated at the indicated concentration in a total volume of 100 μl medium. After 3 days, cell counting kit-8 (Dojindo Molecular Technologies) was used to determine the number of viable cells. Fold changes were calculated using baseline values of vehicle treated cells as a reference (set to 100%).
Flow cytometry
Antibodies used in flow cytometry are mentioned in Supplementary Colony forming assay for mouse cells 10,000 BCR-ABL1-transformed ALL cells or 100,000 CML-like cells were used for this assay. Cells were resuspended in murine MethoCult medium (StemCell Technologies, Vancouver, BC, Canada) and plated on dishes (3 cm in diameter) with an extra dish of water to prevent evaporation. After 7 to 14 days, colonies were counted.
Senescence-associated β-galactosidase assay
This was performed on cytospin preparations as described previously 11 .
DNA extraction and genotyping
Genomic DNA was extracted from mouse cells with NucleoSpin Tissue kit (MACHEREY-NAGEL, Bethlehem, PA) and PCR was performed by using Taq DNA polymerase (NEB, Ipswich, MA). The primer sequences were provided in Supplementary Table 8 .
Gene expression and clinical outcome data
Clinical outcome and gene expression microarray data were derived from the National Cancer Institute TARGET Data Matrix (http://targetnci.nih.gov/dataMatrix/ TARGET_DataMatrix.html) of the Children's Oncology Group (COG) Clinical Trial P9906 and from the Eastern Cooperative Oncology Group (ECOG) Clinical Trial E2993. The end points of the clinical data include minimal residual disease (MRD) after 29 days of treatment (COG), overall survival (OS) and relapse-free survival (RFS) probability (COG and ECOG).
The detailed information about the gene expression microarray data is provided in Supplementary 
Extended Data
Extended a-c, mRNA levels for PECAM1, CD300A and LAIR1 were measured in 207 patients with pediatric ALL (COG P9906). PECAM1, CD300A and LAIR1 mRNA levels for ALL cells from 124 patients that had no detectable minimal residual disease (MRD negative; black) on day 29 in their bone marrow were compared to mRNA levels in 67 patients with positive MRD (red) at the time of bone marrow biopsy (day 29). Based on higher or lower-than median expression levels of PECAM1, CD300A and LAIR1, patients were segregated into two groups (High, n=104/Low, n=103; plots in middle and right). Overall survival (OS; middle) and relapse-free survival (RFS; right) probability was estimated by Kaplan-Meier survival analyses. P-values were calculated by Mann-Whitney-Wilcoxon test (left panels; MRD status) and log rank test (middle and right panels; overall survival and relapse-free survival). d-e, ITAM-based agonists (CD79A, CD79B, IGHM) and ITIM-based inhibitors (PECAM1, CD300A, LAIR1) of pre-BCR signaling were combined into a 6-gene outcome predictor based on "ITAM" and "ITIM" signatures and validated in two clinical trials for adults with Ph + ALL (ECOG E2993) and children with ALL (COG P9906). P-values were calculated by log rank test. f, Lair1 deletion was confirmed by flow cytometry. g, Expression of checkpoint molecules Arf, p53, p21 and p27 was measured by Overall survival of recipient mice in the two groups was compared by Kaplan-Meier analysis (c; P value calculated by log-rank test) and leukemia burden was measured by luciferase bioimaging (d).
